Drugs / EC20
EC20
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed | EU (EMA) | — | progesterone-receptor positive breast cancer | 2012-11-27 | “applications for Conditional Marketing Authorisation for vintafolide, etarfolatide and IV folic acid were submitted based on results in platinum-resistant ovarian cancer patients” merck.com ↗ |
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01748864 | Apr → Oct 2013 | — | Endocyte | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT01953536 | Apr 2014 → Nov 2016 | breast neoplasm | Endocyte | Withdrawn | No outcome recorded |
| Phase 2 | NCT00511485 | Aug 2007 → Jul 2009 | lung adenocarcinoma | Endocyte | Completed | No outcome recorded |
| Phase 2 | NCT00588393 | Sep 2006 → Dec 2007 | Crohn disease, multiple sclerosis, osteoarthritis, rheumatoid arthritis +1 | Mayo Clinic | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01170650 | Apr 2011 → May 2015 | ovarian cancer | Endocyte | Terminated | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 1 | NCT01999738 Background | Oct 2013 → Dec 2017 | non-small cell lung carcinoma | Endocyte | Completed | No outcome recorded |
| Phase 1 | NCT00852189 Background | Apr 2009 → Dec 2011 | cancer | Endocyte | Completed | No outcome recorded |
| Phase 2 | NCT01577654 Background | Mar 2011 → Dec 2013 | non-small cell lung carcinoma | Endocyte | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
All press releases naming this drug 2 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EC20 | “All participants will undergo imaging with the FR targeting investigational imaging agent etarfolatide (EC20, FolateScan) during the screening period to confirm eligibility for...” NCT00511485 ↗6“Etarfolatide (EC20)” NCT01748864 ↗ |
| Known as | Etarfolatide | “EC20 is Etarfolatide, a conjugate of folic acid and a tripeptide moiety that can efficiently chelate the radioisotope 99mTechnetium (99mTc).” NCT01999738 ↗ |
| Known as | FolateScan | “All participants will undergo imaging with the FR targeting investigational imaging agent etarfolatide (EC20, FolateScan) during the screening period to confirm eligibility for...” NCT00511485 ↗ |
| Known as | Technetium Tc 99mEC20 | “FolateScan (Technetium Tc 99mEC20)” NCT00588393 ↗ |
| Modality | Diagnostic / imaging agent | “20-25 mCi 99mTc-EC20 administered IV bolus 1-2 hours prior to imaging” NCT00852189 ↗ |
| Route | Intravenous | “20-25 mCi 99mTc-EC20 administered IV bolus 1-2 hours prior to imaging” NCT00852189 ↗ |